Version 1
: Received: 14 September 2024 / Approved: 15 September 2024 / Online: 17 September 2024 (05:01:39 CEST)
How to cite:
Zeng, W.-J.; Zeng, Y.-F.; Zhou, L.-J.; Yi, J.; Deng, S.; Liu, Z.-Z.; Ye, Q.-Q. The Efficacy and Safety of Oncolytic Viruses in Treatment of Glioma: A Meta-Analysis. Preprints2024, 2024091161. https://doi.org/10.20944/preprints202409.1161.v1
Zeng, W.-J.; Zeng, Y.-F.; Zhou, L.-J.; Yi, J.; Deng, S.; Liu, Z.-Z.; Ye, Q.-Q. The Efficacy and Safety of Oncolytic Viruses in Treatment of Glioma: A Meta-Analysis. Preprints 2024, 2024091161. https://doi.org/10.20944/preprints202409.1161.v1
Zeng, W.-J.; Zeng, Y.-F.; Zhou, L.-J.; Yi, J.; Deng, S.; Liu, Z.-Z.; Ye, Q.-Q. The Efficacy and Safety of Oncolytic Viruses in Treatment of Glioma: A Meta-Analysis. Preprints2024, 2024091161. https://doi.org/10.20944/preprints202409.1161.v1
APA Style
Zeng, W. J., Zeng, Y. F., Zhou, L. J., Yi, J., Deng, S., Liu, Z. Z., & Ye, Q. Q. (2024). The Efficacy and Safety of Oncolytic Viruses in Treatment of Glioma: A Meta-Analysis. Preprints. https://doi.org/10.20944/preprints202409.1161.v1
Chicago/Turabian Style
Zeng, W., Zheng-Zheng Liu and Qian-Qian Ye. 2024 "The Efficacy and Safety of Oncolytic Viruses in Treatment of Glioma: A Meta-Analysis" Preprints. https://doi.org/10.20944/preprints202409.1161.v1
Abstract
Objective: The main purpose of this meta-analysis was to assess the efficacy and safety of Oncolytic Viruses (OVs) in glioma therapy. Methods: We searched the literature in PubMed, EMBASE, Web of Science, and the Cochrane Library. The primary outcomes assessed were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs). The risk of bias was evaluated by sensitivity analysis and publication bias. Results: We identified 21 studies with 440 patients in this meta-analysis. In the single-arm analysis, the results showed that the 1-year OS rate was 47% (95% CI: 34%-61%, I2 = 75%) and the 2-year OS rate was 14% (95% CI: 10%-20%, I2 = 0%). The median OS was 12.48 months (95% CI: 10.71-14.25, I2 = 96%). The 1-year PFS rate was 13% (95% CI: 5%-24%, I2 = 0%), with the median PFS being 4.01 months (95% CI: 2.99-45.03, I2 = 96%). The pooled estimate of ORR was 7% (95% CI: 3%-12%, I2 = 23%). Funnel plots for median PFS were asymmetric with Egger’s test P < 0.01 indicating publication exists. The incidence of OVs-related AEs was 49% (95% CI: 20%-79%, I2 = 95%), and AEs > grade 3 was 8% (95% CI: 3%-16%, I2 = 62%). Conclusion: This meta-analysis indicated that OVs therapy was relatively safe but did not significantly extend survival in patients with gliomas.
Keywords
Glioma; Oncolytic viruses; Drug efficacy; Drug safety; Meta-analysis
Subject
Medicine and Pharmacology, Pharmacy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
